Obolenskoe

Obolenskoe is a leading Russian pharmaceutical company focused on the development, production, and commercialization of high-quality generic and innovative medications. Founded in 1994 and headquartered in the Moscow region, the company maintains a robust portfolio of over 150 products across diverse therapeutic areas including gastroenterology, cardiology, and neurology. In 2019, Obolenskoe merged with Binnopharm to form a major pharmaceutical cluster under the Alium brand, which is now part of the Binnopharm Group. The company operates state-of-the-art manufacturing facilities that comply with international GMP standards. Obolenskoe is recognized for its strong market presence in Russia, particularly with well-known brands like Venarus and Neobutin.